Assenagon Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.57M | Sell |
60,227
-333,228
| -85% | -$41.9M | 0.01% | 480 |
|
|
2025
Q1 | $43.5M | Buy |
393,455
+367,315
| +1,405% | +$40.6M | 0.07% | 217 |
|
|
2024
Q4 | $3.57M | Sell |
26,140
-3,663
| -12% | -$500K | 0.01% | 755 |
|
|
2024
Q3 | $3.43M | Sell |
29,803
-219,621
| -88% | -$25.3M | 0.01% | 783 |
|
|
2024
Q2 | $34.3M | Sell |
249,424
-88,313
| -26% | -$12.2M | 0.08% | 178 |
|
|
2024
Q1 | $46.6M | Buy |
337,737
+22,177
| +7% | +$3.06M | 0.11% | 132 |
|
|
2023
Q4 | $41.6M | Sell |
315,560
-268,979
| -46% | -$35.4M | 0.11% | 135 |
|
|
2023
Q3 | $65.8M | Buy |
584,539
+319,564
| +121% | +$36M | 0.2% | 74 |
|
|
2023
Q2 | $25M | Buy |
264,975
+174,467
| +193% | +$16.5M | 0.09% | 175 |
|
|
2023
Q1 | $9.16M | Sell |
90,508
-117,923
| -57% | -$11.9M | 0.03% | 389 |
|
|
2022
Q4 | $24.9M | Buy |
208,431
+123,613
| +146% | +$14.8M | 0.09% | 194 |
|
|
2022
Q3 | $9.01M | Sell |
84,818
-54,653
| -39% | -$5.81M | 0.03% | 344 |
|
|
2022
Q2 | $13.6M | Buy |
139,471
+125,611
| +906% | +$12.2M | 0.05% | 283 |
|
|
2022
Q1 | $1.3M | Sell |
13,860
-71,965
| -84% | -$6.74M | ﹤0.01% | 955 |
|
|
2021
Q4 | $7.31M | Buy |
85,825
+74,634
| +667% | +$6.36M | 0.02% | 382 |
|
|
2021
Q3 | $1.07M | Sell |
11,191
-37,878
| -77% | -$3.63M | ﹤0.01% | 848 |
|
|
2021
Q2 | $4.78M | Buy |
49,069
+45,836
| +1,418% | +$4.46M | 0.02% | 462 |
|
|
2021
Q1 | $314K | Buy |
+3,233
| New | +$314K | ﹤0.01% | 1056 |
|
|
2020
Q3 | – | Sell |
-22,926
| Closed | -$2.8M | – | 1238 |
|
|
2020
Q2 | $2.8M | Buy |
+22,926
| New | +$2.8M | 0.02% | 468 |
|
|
2019
Q4 | – | Sell |
-24,885
| Closed | -$2.24M | – | 836 |
|
|
2019
Q3 | $2.24M | Buy |
+24,885
| New | +$2.24M | 0.02% | 347 |
|